AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination Oct 2 (Reuters) - AstraZeneca AZN.L and Daiichi Sankyo 4568.T have entered into a clinical collaboration with Summit Therapeutics SMMT.O to test their cancer drug, Datroway, in combination with Summit's ivonescimab across multiple tumour types, including lung and breast cancers.
The companies said on Friday that they intend to begin with a Phase III trial in first-line triple-negative breast cancer
The deal builds on AstraZeneca's $2 billion investment in Summit to collaborate on a series of studies testing their cancer treatments together
Under the agreement, each company will contribute its respective medicine and share trial costs, while retaining development and commercial rights to their own drugs
(Reporting by Nithyashree R B in Bengaluru; Editing by Mrigank Dhaniwala)
((NithyashreeRB@thomsonreuters.com))
Recent news on AstraZeneca
See all newsBrief: AstraZeneca Says ZEGFROVY 200 Mg Administered Orally Once Daily Now Available In US
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: Abu Dhabi Biobank Partners With Astrazeneca To Advance Predictive Healthcare - AD Media Office
UK Stocks-Factors to watch on October 22 (updated)
Brief: AstraZeneca Says Ultomiris Approved In Us In IgAN